Mikael Åberg
Researcher at Department of Medical Sciences; Coagulation and inflammation science
- Telephone:
- +46 18 611 42 53
- E-mail:
- Mikael.Aberg@medsci.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 61, 3 tr
- Postal address:
- Akademiska sjukhuset, Ingång 40, 5 tr
751 85 UPPSALA
Researcher at Department of Medical Sciences; Clinical Biomarkers Facility
- E-mail:
- mikael.aberg@medsci.uu.se
- Visiting address:
- BMC, D11:208B, Husargatan 3
752 37 Uppsala - Postal address:
- Clin Biomarkers Facility, BMC, Box 392
751 06 Uppsala
More information is available to staff who log in.
Publications
Selection of publications
- Next generation pan-cancer blood proteome profiling using proximity extension assay (2023)
- Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose (2023)
- SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters (2023)
- Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination (2023)
- SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants (2023)
- Mucosal IgA protects against BQ.1 and BQ.1.1 infection (2023)
- 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection (2023)
- Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers (2023)
- Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection (2022)
- Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. (2022)
- Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time (2022)
- Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection (2022)
- Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19 (2022)
- Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines (2022)
- Periodontal Disease Augments Cardiovascular Disease Risk Biomarkers in Rheumatoid Arthritis (2022)
- AGPAT1 as a Novel Colonic Biomarker for Discriminating Between Ulcerative Colitis With and Without Primary Sclerosing Cholangitis (2022)
- Detection of SARS-CoV-2 antibodies in serum and dried blood spot samples of vaccinated individuals using a sensitive homogeneous proximity extension assay (2022)
- Platelet-leukocyte aggregate formation and inflammation in patients with pulmonary arterial hypertension and CTEPH (2022)
- Urinary cytokines correlate with acute kidney injury in critically ill COVID-19 patients (2021)
- Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 (2021)
- Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. (2021)
- Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease (2021)
- Role of Extracellular Vesicles in Pulmonary Arterial Hypertension Modulation of Pulmonary Endothelial Function and Angiogenesis (2020)
- Activation of β1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival (2020)
- Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner (2019)
- Tissue factor in ulcerative colitis, with and without concomitant primary sclerosing cholangitis. (2019)
- Adipocytes are coagulant active in a TF/FVIIa dependent manner but lipolysis is unaffected by TF/FVIIa (2018)
- Proteomic, functional and receptor studies of growth differentiation factor 15, GDF-15 (2018)
- Sensitive detection of platelet-derived and tissue factor positive extracellular vesicles in plasma using solid-phase proximity ligation assay (2018)
- Sensitive and Specific Detection of Platelet-Derived and Tissue Factor-Positive Extracellular Vesicles in Plasma using Solid-Phase Proximity Ligation Assay (2018)
- Activation of beta1-integrins and caveolin-1 by TF/FVIIa promotes cell survival (2018)
- IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets (2017)
- Tissue factor/FVIIa transactivates the IGF-1R by a Src-dependent phosphorylation of caveolin-1 (2016)
- Tissue Factor Noncoagulant Signaling (2015)
- Tissue factor/FVIIA transactivates the IGF-1R in prostate cancer cells via inhibition of caveolin-1 (2015)
- Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor (2014)
- The insulin-like growth factor 1 receptor mediates tissue factor/FVIIa-induced cell survival (2013)
- Tissue Factor non-coagulant signalling - molecular mechanisms and biological consequences with focus on cell migration and apoptosis (2013)
- A quantitative real-time PCR method for tissue factor mRNA (2003)
- A two-step proteomic approach identifies candidate biomarker in ulcerative colitis with concomitant primary sclerosing cholangitis.
Recent publications
- Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023 (2024)
- Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum (2024)
- Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia (2024)
- Next generation pan-cancer blood proteome profiling using proximity extension assay (2023)
- Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia (2023)
All publications
Articles
- Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023 (2024)
- Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum (2024)
- Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia (2024)
- Next generation pan-cancer blood proteome profiling using proximity extension assay (2023)
- Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia (2023)
- Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection (2023)
- Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose (2023)
- SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters (2023)
- Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination (2023)
- SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants (2023)
- Mucosal IgA protects against BQ.1 and BQ.1.1 infection (2023)
- 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection (2023)
- Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers (2023)
- Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21) (2023)
- Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection (2022)
- Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. (2022)
- Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time (2022)
- Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection (2022)
- Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19 (2022)
- Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines (2022)
- Periodontal Disease Augments Cardiovascular Disease Risk Biomarkers in Rheumatoid Arthritis (2022)
- AGPAT1 as a Novel Colonic Biomarker for Discriminating Between Ulcerative Colitis With and Without Primary Sclerosing Cholangitis (2022)
- Detection of SARS-CoV-2 antibodies in serum and dried blood spot samples of vaccinated individuals using a sensitive homogeneous proximity extension assay (2022)
- Platelet-leukocyte aggregate formation and inflammation in patients with pulmonary arterial hypertension and CTEPH (2022)
- Urinary cytokines correlate with acute kidney injury in critically ill COVID-19 patients (2021)
- Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 (2021)
- Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. (2021)
- Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease (2021)
- Role of Extracellular Vesicles in Pulmonary Arterial Hypertension Modulation of Pulmonary Endothelial Function and Angiogenesis (2020)
- Activation of β1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival (2020)
- Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner (2019)
- Tissue factor in ulcerative colitis, with and without concomitant primary sclerosing cholangitis. (2019)
- Adipocytes are coagulant active in a TF/FVIIa dependent manner but lipolysis is unaffected by TF/FVIIa (2018)
- Proteomic, functional and receptor studies of growth differentiation factor 15, GDF-15 (2018)
- Sensitive detection of platelet-derived and tissue factor positive extracellular vesicles in plasma using solid-phase proximity ligation assay (2018)
- Sensitive and Specific Detection of Platelet-Derived and Tissue Factor-Positive Extracellular Vesicles in Plasma using Solid-Phase Proximity Ligation Assay (2018)
- Activation of beta1-integrins and caveolin-1 by TF/FVIIa promotes cell survival (2018)
- IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets (2017)
- Tissue factor/FVIIa transactivates the IGF-1R by a Src-dependent phosphorylation of caveolin-1 (2016)
- Tissue Factor Noncoagulant Signaling (2015)
- Tissue factor/FVIIA transactivates the IGF-1R in prostate cancer cells via inhibition of caveolin-1 (2015)
- Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor (2014)
- The insulin-like growth factor 1 receptor mediates tissue factor/FVIIa-induced cell survival (2013)
- Tissue Factor non-coagulant signalling - molecular mechanisms and biological consequences with focus on cell migration and apoptosis (2013)
- A quantitative real-time PCR method for tissue factor mRNA (2003)
- A two-step proteomic approach identifies candidate biomarker in ulcerative colitis with concomitant primary sclerosing cholangitis.
- Monitoring SARS-CoV-2 IgA, IgM and IgG antibodies in blood and saliva samples using antibody proximity extension assays (AbPEA)